Global Real-World Evidence (RWE) Solutions Market is valued at USD 2206.1 Million in 2021 and is expected to reach USD 4312.6 Million by 2028 with a CAGR of 11.82% over the forecast period.
Global Real-World Evidence (RWE) Solutions Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2028. Rapid increase in drug development activities and growing government support to attempt medical research are some of the major factors driving the growth of the Global Real-World Evidence (RWE) Solutions Market.
Real-World Evidence (RWE) is a fully integrated solution to ensure end users have the right evidence at the right time to know value-based terms in relevant, correct and compelling manner. From the healthcare perspective, real-world evidence is the clinical evidence involving the usage and potential benefits or risks of a medical product which can be derived from analysis of real-world data (RWD). Real-world evidence (RWE) can be generated by different levels of analysis. The development of RWE needs a high-powered analytics, a validated approach and a robust knowledge of available real world data RWD sources. Real-world evidence (RWE) solution is used to monitor post market safety and helps in generating regulatory decisions.
Covid-19 has shown a slightly positive upturn on the real-world evidence (RWE) solutions market. The covid-19 pandemic has triggered competition level in the evidence industry to create safe and effective therapies and vaccines. This real type of evidence accelerates research and development methodologies as well as made the health care community more receptive to expand the use of RWE beyond traditional safety-related applications.
Global real-world evidence (RWE) solutions market is segmented into component, application, end User and geography. Based on component, the global real-world evidence (RWE) solutions market is segmented into datasets, clinical setting data, claims data, pharmacy data, services, and others. Based on application, the market is divided into market oncology, neurology, immunology, cardiovascular diseases, other. Based on end user, the market is divided into healthcare payers, healthcare providers, pharmaceutical & medical device companies, and others.
Some of the key players for global Real-World Evidence (RWE) Solutions are
On August 9th, 2021; IQVIA announced a new partnership with real world research leader named HealthCore. Together, these companies will promote real world evidence (RWE) evolutionary studies. The collaboration has improved data analysis and took focus on the use of de-identified real-world data (RWD) from patients with Covid-19 disease. IQVIA is increased their focus to enhance evidence generation with the goal of advancing patient health and clinical outcomes.
The growth of the real-world evidence (RWE) solutions market is primarily driven by increasing usage of electronic health records (EHRs) and rapid advancements of drug development in pharma industry. From the last few years, pharma industry has significantly realised the value of real-world evidence (RWE) solutions for improving traditional clinical studies, extending its use beyond the usual pharmacoepidemiologic safety. For example; globally the pharmaceutical market was valued at around USD 1.0 trillion in 2019 at a three to six percent compound annual growth rate over the next five years. Nearly 90% of global pharmaceutical companies will be using real world data or evidence solutions within the forecast period. Likewise, rising demand for drug development and clinical decision-making in the life sciences industry is another driving factor for the growth of real-world evidence (RWE) solutions market.
Regardless above driving factors, operational challenges in real-world evidence solutions include different key issues such as feasibility, governance, and sustainability may obstruct the real-world evidence (RWE) solutions market growth. In spite of that, real-world evidence (RWE) solutions emerge as a new source of opportunities for clinical evidence as well as advanced machine learning (ML) techniques are being used in RWE are promising tools for precision medicine.
North America is anticipated to account for the largest market share in the real-world evidence (RWE) solutions market. North America’s market growth is likely to be accelerated by some major factors such as large base of drug development companies as well as rising focus towards research & development activities to collect and analyze real time data. The use of RWE is also gaining the popularity in North America and is currently being evaluated by regulatory authorities for potential use for labelling changes. For example; the U.S. Food and Drug Administration (FDA) has been creating the FDA Real-World Evidence Program Framework to analyze the use of RWE throughout the drug development process.
Asia pacific is the fastest growing region in the real-world evidence (RWE) solutions market due to increased government support to carry out medical research and increased use of latest innovative technologies. The utilization of real-world evidence (RWE) is an emerging part for the medical device industry, regulators and policy makers. For example; government organizations have announced a key consideration for Policymakers to explore the state of policy innovation regarding the use of RWE for regulatory and reimbursement decision-making. For example, Asia-Pacific accounted for around 43.98% share of global clinical trials activity in 2020, with an increase of nearly 6.54%.
North America
Europe
Asia-Pacific
Latin America
Middle East and Africa
Report Analysis | Details |
---|---|
Historical data | 2018 - 2021 |
Forecast Period | 2021 - 2028 |
Market Size in 2021: | USD 2206.1 Million |
Base year considered | 2021 |
Forecast Period CAGR %: |
11.82% |
Market Size Expected in 2028: | USD 4312.6 Million |
Tables, Charts & Figures: | 175 |
Pages | 200 |
Real-World Evidence (RWE) Solutions Companies | ICON plc, IQVIA Holdings Inc., PPD Inc., SYNEOS HEALTH Inc., CLARIVATE PLC, Medpace Holdings Inc., Symphony Innovation LLC, Clinigen Group plc, Cognizant Technology Solutions Corporation, IBM Corporation, Oracle Corporation, PAREXEL International Corporation, PerkinElmer Inc., SAS Institute Inc., UnitedHealth Group Incorporated, Flatiron Health, Others |
Segments Covered | By Component, By Application, By End User |
Regional Analysis | North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa |
+44-1173181773
sales@brandessenceresearch.com
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us hr@brandessenceresearch.com
JOIN USFIND ASSISTANCE
LONDON OFFICE
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
FOLLOW US
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®